DEXA sales pace Hologic revenues
Bone densitometry firm Hologic enjoyed a strong fiscal 1996 thanksto higher sales of its Acclaim series of dual-energy x-ray bonedensitometers. The Waltham, MA, company's acquisition of miniC-arm manufacturer FluoroScan Imaging Systems also contributedto
Bone densitometry firm Hologic enjoyed a strong fiscal 1996 thanksto higher sales of its Acclaim series of dual-energy x-ray bonedensitometers. The Waltham, MA, company's acquisition of miniC-arm manufacturer FluoroScan Imaging Systems also contributedto Hologic's revenue growth.
For the year (end-September), Hologic posted revenues of $91.6million, up 62% compared with sales of $56.5 million in fiscal1995. The company's net income for the year stood at $11.4 million,compared with $3.3 million the year before, when a legal battlewith Lunar squeezed Hologic's profits.
For the fourth quarter, Hologic had revenues of $24.4 million,up 46% compared with sales of $16.7 million in the fourth quarterof 1995. The company's net income was $2.1 million, compared with$988,000 in the same period a year ago.
While the FluoroScan acquisition added over $3 million in salesto Hologic's fourth quarter, most of the company's growth camethrough sales in the bone densitometry segment: Hologic's revenuein the period would have grown 64% without the FluoroScan acquisition.Sales of Acclaim systems reached record levels in the U.S. dueto new drugs for treating osteoporosis, according to Hologic chairmanand CEO David Ellenbogen.
Strategies to Reduce Disparities in Interventional Radiology Care
March 19th 2025In order to help address the geographic, racial, and socioeconomic barriers that limit patient access to interventional radiology (IR) care, these authors recommend a variety of measures ranging from increased patient and physician awareness of IR to mobile IR clinics and improved understanding of social determinants of health.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Study: Monitoring of Prostate MRI Exams Could Lead to 75 Percent Reduction of Gadolinium Contrast
March 17th 2025While DCE MRI was deemed helpful in over 67 percent of cases in which it was used, researchers found that monitored prostate MRI exams, which facilitated a 75 percent reduction of DCE MRI sequences, had comparable sensitivity for prostate cancer as non-monitored exams.
